Preventing Preterm Birth: Exploring Innovative Solutions.

This review examines the complexities of preterm birth (PTB), emphasizes the pivotal role of inflammation in the pathogenesis of preterm labor, and assesses current available interventions. Antibiotics, progesterone analogs, mechanical approaches, nonsteroidal anti-inflammatory drugs, and nutritional supplementation demonstrate a limited efficacy. Tocolytic agents, targeting uterine activity and contractility, inadequately prevent PTB by neglecting to act on uteroplacental inflammation. Emerging therapies targeting toll-like receptors, chemokines, and interleukin receptors exhibit promise in mitigating inflammation and preventing PTB.
Competing Interests: Disclosure S. Chemtob and W.D. Lubell hold a patent on composition of matter for the use of 101.10/rytvela (IL-1 receptor antagonists, compositions, and methods of treatment, United States patent no. USPTO8618054, May 5, 2005). S Chemtob, WD Lubell, DM Olson, and S Girard hold a patent on methods for reducing perinatal morbidity and/or mortality (US20210322509, March 9, 2016).
(Copyright © 2024 Elsevier Inc. All rights reserved.)